The Concordance between Mumps and Rubella Sero-Positivity among the Israeli Population in 2015.

Abstract

Mumps and rubella are vaccine-preventable viral diseases through the measles-mumps-rubella-varicella (MMRV) vaccine, administered at 12 months and again at 6 years. We assessed the sero-prevalence of mumps and rubella, identified factors associated with sero-negativity, and evaluated concordance between mumps and rubella sero-positivity. A national cross-sectional sero-survey was conducted on samples collected in 2015 by the Israel National Sera Bank. Samples were tested for mumps and rubella IgG antibodies using an enzyme-linked immunosorbent assay. Of 3131 samples tested for mumps IgG, 84.8% (95%CI: 83.5-86.0%) were sero-positive. Sero-negativity for mumps was significantly associated with age (high odds ratios observed in infants younger than 4 years and 20-29 years old subjects). Of 3169 samples tested for rubella IgG antibodies, 95.2% (95%CI: 94.4-95.9%) were sero-positive. Rubella sero-negativity was significantly associated with age (high odds ratios observed in children younger than 4 years old and adults older than 30 years), males, Jews, and others. Concordant sero-positivity for both mumps and rubella viruses was observed in 83.9% of the tested samples. The Israeli population was sufficiently protected against rubella but not against mumps. Since both components are administered in the MMRV vaccine simultaneously, the mumps component has a lower uptake than rubella and quicker waning.

• Authors: Ravit Bassal, Tamy Shohat, Tal Levin, Rakefet Pando, Eilat Shinar, Doron Amichay, Mira Barak, Anat Ben-Dor, Adina Bar-Haim, Ella Mendelson, Dani Cohen, Lital Keinan-Boker, Victoria Indenbaum
• Journal: Vaccines (Vaccines (Basel)) Vol. 10 Issue 7 (Jun 22 2022) ISSN: 2076-393X [Print] Switzerland
• PMID: 35891160 (Publication Type: Journal Article)